Impact Factor 2.635 | CiteScore 2.99
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Neurol. | doi: 10.3389/fneur.2019.00908

Adult stem cells and induced pluripotent stem cells for stroke treatment

  • 1Servicio Gallego de Salud, Spain
  • 2Health Research Institute of Santiago of Compostela (IDIS), Spain

Stroke is the main cause of disability and death in the world within neurological diseases. Despite such a huge impact, enzymatic or mechanical recanalization are the only treatments available so far for ischemic stroke, but only less than 20% of patients can benefit from them. The use of stem cells as a possible cell therapy in stroke has been tested for years. The results obtained from these studies, although conflicting or controversial in some aspects, are promising. In the last years, the recent development of the induced pluripotent stem cells has opened new possibilities to find new cell therapies against stroke. In this review, we will provide an overview of the state of the art of cell therapy in stroke. We will describe the current situation of the most employed stem cells and the use of induced pluripotent stem cells in stroke pathology. We will also present a summary of the different clinical trials that are being carried out or that already have results on the use of stem cells as a potential therapeutic intervention for stroke.

Keywords: adult stem cell, cell therapy, Clinical Trial, induced pluripotent stem cell, Stroke

Received: 19 May 2019; Accepted: 05 Aug 2019.

Copyright: © 2019 Campos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Francisco Campos, Servicio Gallego de Salud, Santiago de Compostela, Spain, francisco.campos.perez@sergas.es